遠大醫藥(00512.HK)TLX591獲批加入國際多中心III期臨床試驗
遠大醫藥(00512.HK)公布,集團用於治療前列腺癌的全球創新在研放射性核素偶聯藥物(RDC)TLX591(177Lu-rosopatamab tetraxetan)加入國際多中心III期臨床試驗的申請,近日已獲得中華人民共和國國家藥品監督管理局默示許可。
此前,集團於2020年11月與Telix Pharmaceutical Limited(TLX.US)與其全球子公司簽署了產品戰略合作協議,並獲得其開發的包括TLX591、TLX591-CDx、TLX250-CDx在內的多款創新RDC產品在大中華區的獨家權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.